Wellmarker Bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$361K
- Investors
-
27
Wellmarker Bio General Information
Description
Developer of anticancer drugs designed to treat cancer patients with medical advancements. The company specializes in developing predictive biomarkers and first-in-class drugs through profound research know-how and a research Institute that comprises a target discovery department, drug discovery department, and medicinal chemistry department, enabling healthcare providers to cure their patients and improve their lives.
Contact Information
Website
www.wmbio.coCorporate Office
- 947 Hanam-daero
- 808 S-dong Pungsan-dong, Hanam Techno Valley U1 Center
- Hanam, Gyeonggi
- South Korea
Corporate Office
- 947 Hanam-daero
- 808 S-dong Pungsan-dong, Hanam Techno Valley U1 Center
- Hanam, Gyeonggi
- South Korea
Wellmarker Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 31-Jul-2024 | $361K | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series C) | 01-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series B) | 14-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series B) | 05-Jul-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 08-Oct-2018 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 01-Apr-2018 | $4.34M | $4.34M | Completed | Clinical Trials - General | |
| 1. Corporate | 27-Dec-2016 | $2.11K | $2.11K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Wellmarker Bio Patents
Wellmarker Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024205282-A1 | Igsf1-specific binding protein and use thereof | Inactive | 29-Mar-2023 | ||
| WO-2024090916-A1 | Pharmaceutical composition for cancer treatment comprising anti-igsf1 antibody | Inactive | 24-Oct-2022 | ||
| WO-2023229303-A1 | Antibody binding to c-terminus of igsf1 and use thereof | Inactive | 23-May-2022 | ||
| WO-2023211073-A1 | Biomarker composition for predicting cancer patient susceptibility to anti-igsf1 antibody, and method using same | Inactive | 25-Apr-2022 | ||
| WO-2023211068-A1 | Pharmaceutical composition for cancer treatment, comprising anti-igsf1 antibody and anti-pd-1 antibody | Inactive | 25-Apr-2022 | C07K16/2803 |
Wellmarker Bio Signals
Wellmarker Bio Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Elohim Partners | PE/Buyout | Minority | ||
| GeneN Investment Partners | Venture Capital | Minority | ||
| GTOG Private Equity | PE/Buyout | Minority | ||
| Laguna Investment | Venture Capital | Minority | ||
| LS Securities | Investment Bank | Minority |
Wellmarker Bio FAQs
-
When was Wellmarker Bio founded?
Wellmarker Bio was founded in 2016.
-
Where is Wellmarker Bio headquartered?
Wellmarker Bio is headquartered in Hanam, South Korea.
-
What is the size of Wellmarker Bio?
Wellmarker Bio has 7 total employees.
-
What industry is Wellmarker Bio in?
Wellmarker Bio’s primary industry is Drug Discovery.
-
Is Wellmarker Bio a private or public company?
Wellmarker Bio is a Private company.
-
What is Wellmarker Bio’s current revenue?
The current revenue for Wellmarker Bio is .
-
How much funding has Wellmarker Bio raised over time?
Wellmarker Bio has raised $41.8M.
-
Who are Wellmarker Bio’s investors?
Elohim Partners, GeneN Investment Partners, GTOG Private Equity, Laguna Investment, and LS Securities are 5 of 27 investors who have invested in Wellmarker Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process